Eastgate Biotech Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep '17 Sep 30, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Net Income	-3.82	-2.98	-4.28	-4.91	-1.72	-0.62
Depreciation & Amortization	0.07	-	0.04	0.03	0.01	-
Asset Writedown & Restructuring Costs	-	0.18	-	-	-	-
Stock-Based Compensation	0.51	0.83	1.05	1.48	-	0.05
Other Operating Activities	-0.01	-0.01	-0.01	0	0.08	0.34
Change in Accounts Payable	0.84	0.02	0.1	0.05	0.19	0.22
Change in Unearned Revenue	0	0.07	0.03	-	-	-
Change in Other Net Operating Assets	0.4	1.49	2.5	2.11	1.02	0.01
Operating Cash Flow	-1.76	-0.39	-0.57	-1.24	-0.41	-
Capital Expenditures	-0.05	-	-	-0.1	-0.02	-
Investing Cash Flow	-0.05	-	-	-0.1	-0.02	-
Short-Term Debt Issued	-	0.33	0.31	0.19	0.37	0.1
Total Debt Issued	1.78	0.33	0.31	0.19	0.37	0.1
Short-Term Debt Repaid	-	-	-0	-0.09	-	-
Long-Term Debt Repaid	-	-0.01	-0.01	-0.02	-0.04	-
Total Debt Repaid	-0.14	-0.01	-0.01	-0.11	-0.04	-
Net Debt Issued (Repaid)	1.63	0.32	0.3	0.08	0.33	0.1
Issuance of Common Stock	0.12	-	0.03	1.55	-	-
Financing Cash Flow	1.75	0.32	0.33	1.63	0.33	0.1
Foreign Exchange Rate Adjustments	0.06	0.05	-0.03	0	0	-
Net Cash Flow	0	-0.02	-0.27	0.29	-0.1	0.1
Free Cash Flow	-1.81	-0.39	-0.57	-1.34	-0.43	-
Free Cash Flow Margin	-1314.10%	-	-430.56%	-	-	-
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.03	-0.01	-
Cash Interest Paid	0	0.01	0	0	0	-
Levered Free Cash Flow	-	-	-1.09	-2.32	0.13	-
Unlevered Free Cash Flow	-	-	-1.02	-2.26	0.17	-
Change in Working Capital	1.49	1.58	2.63	2.15	1.22	0.23

Updated Mar 4, 2019. Source: S&P Global Market Intelligence. Standard template. Financial Sources.